Retina

OCU410ST is a modifier gene therapy candidate being developed for Stargardt disease, which affects approximately 100,000 people in the United States and Europe combined.

The second and third required PPQ batches are scheduled, and should they meet specifications, the new TRIESENCE production process will be complete, allowing Harrow to relaunch during 2024.

The role of calendars may be growing more important when managing patients with nAMD and DME. How many weeks can patients go between injections with newer anti-VEGF agents versus older options? How short of an injection interval can patients tolerate before it becomes too much of a burden? In this podcast, Murtaza Adam, MD; Laxmi Devisetty, MD, Hong-Uyen Hua, MD; and Sherrol Reynolds, OD; share insights into determining appropriate treatment regimens with these therapies and supporting patient adherence.

A priority review has been granted with a PDUFA goal date set for December 17, 2024.

We stand on the cusp of a new era in vitreoretinal surgery, one that has been marked by only a select few seminal innovations

XLRP often leads to blindness by middle age with no treatment options currently available

The company highlighted successful enrollment in the SOL-1 Phase 3 trial for wet AMD, plans for a new repeat dosing study (SOL-R), and positive 48-week data from the Phase 1 HELIOS study for NPDR

The mapping method revealed prominent microscopic abnormalities consistent with DR

Paying attention to high-resolution OCT is more important than ever

The NP-1/NP-1C preloaded IOL injector has already been made available in parts of Asia

VISTA is a global randomly assigned, controlled, masked, multi-center pivotal study evaluating the efficacy, safety, and tolerability of 2 dose levels of AGTC-501 for the treatment of X-linked retinitis pigmentosa

Researchers examined data of more than 200,000 people, some at an early stage of the disease and some without age-related eyesight issues

Authors pointed out that understanding this link may aid with genetic counseling or surveillance of affected individuals, potentially contributing to improved management and outcomes.

Investigators put forth a list of considerations for surgeons ahead of lens removalin paediatric patients

Investigators reported findings from the first study of successful macular hole closure using topical therapy

The flagship, light-based technology has received approval for applications in the anterior and posterior segments

The COVID-19 pandemic changed medicine forever, and now scientists are forging a new path for healthcare in the future, including in ophthalmology.

According to researchers at Waseda University in Japan, the proposed device can measure electrical potentials from different places in the retina simultaneously, which is useful in diagnosing eye diseases.

McDonnell stays focused on helping the next generation of ophthalmologists launch their careers in academics.

The approval also grants Outlook Therapeutics an initial 10 years of market exclusivity in the EU for bevacizumab gamma (LYTENAVA)

Analysis of the OAKS and DERBY trials showed reduced growth rates of SD-OCT biomarkers for geographic atrophy

Professor Lois accepted the award at the Royal College of Ophthalmologists Annual Congress

David Almeida, MD, PhD, MBA, shared insights on the surgical tools he uses in his practice at the 2024 Retina World Congress meeting in Fort Lauderdale, Florida.

The agency issued approval for Yesafili, from Biocon Biologics, and Opuviz, from Samsung Bioepis and Biogen